Search

Displaying results 2051 - 2060 of 6831 in total
  1. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    and cardiovascular disease due to their vasoconstrictive properties. … safer for use in patients with contraindications to standard therapy.

  2. Drug

    Racepinephrine

    go.drugbank.com/drugs/DB11124
    Approved

    Racepinephrine is a racemic mixture consisting of d-DB00668 and l-DB00668 enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermitt...

    Mixtures: Racord Two No 8, Racord Two No 9Products: Sil Trax Epi No 8, Sil Trax Epi No 9
  3. Drug

    Taurine

    go.drugbank.com/drugs/DB01956
    ApprovedInvestigationalNutraceutical

    [A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat. … [L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label]

  4. Drug

    Tizanidine

    go.drugbank.com/drugs/DB00697
    ApprovedInvestigational

    Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.

  5. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. … [L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin].

    Synonyms: 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea
  6. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.

    Synonyms: DB-OTO
  7. Drug

    Cisatracurium

    go.drugbank.com/drugs/DB00565
    ApprovedInvestigational

    [A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release.[A253597] … This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.

  8. Drug

    Tesamorelin

    go.drugbank.com/drugs/DB08869
    ApprovedInvestigational

    Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.

  9. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix]. … by preventing intramyometrial growths in the endometrial glands.